Effect of Metformin and Rosiglitazone Over no Diabetic With Metabolic Syndrome Patients.
Status:
Completed
Trial end date:
2009-01-01
Target enrollment:
Participant gender:
Summary
To compare the effect of insulin sensitizing drugs (metformin and rosiglitazone) over glucose
homeostasis (GH) in no diabetic metabolic syndrome individuals. A randomized blinded clinical
trial did in patients with metabolic syndrome (n=30), without diabetes. Prior to detailed
information and signature of informed consent by patients were done three treatment groups by
randomized technique; a) Placebo, b) Metformin (850 mg/day), c) Rosiglitazone (4 mg/day),
treatment was administered for 8 weeks. GH was measured before and after treatment using oral
glucose tolerance test (OGTT), and IR-index (Homeostatic Model). Determination was performed
on weight, size, body mass index, plicometry, blood pressure, fasting glucose levels,
triglycerides, HDL-cholesterol and insulin.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
J JESUS VENEGAS, MD
Collaborators:
Instituto Mexicano del Seguro Social National Council of Science and Technology, Mexico